0001209191-15-002172.txt : 20150106
0001209191-15-002172.hdr.sgml : 20150106
20150106161745
ACCESSION NUMBER: 0001209191-15-002172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150102
FILED AS OF DATE: 20150106
DATE AS OF CHANGE: 20150106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAPLAN GILLA
CENTRAL INDEX KEY: 0001247024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 15510233
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
FORMER NAME:
FORMER CONFORMED NAME: KAPLAN GILLA PHD
DATE OF NAME CHANGE: 20030625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-01-02
0
0000816284
CELGENE CORP /DE/
CELG
0001247024
KAPLAN GILLA
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
1
0
0
0
Common Stock
79508
D
Common Stock
2015-01-02
4
M
0
45536
16.2125
A
45536
I
By family trust
Common Stock
2015-01-02
4
S
0
45536
113.4736
D
0
I
By family trust
Stock Option (right to buy)
16.2125
2015-01-02
4
M
0
45536
0.00
D
2015-12-29
Common Stock
45536
0
I
By family trust
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold by two family trusts (the trustee of which is Dr. Kaplan's brother-in-law and the beneficiaries of which are Dr. Kaplan's immediate family members) pursuant to Rule 10b5-1 plans in multiple transactions at prices ranging from $112.65 to $114.35, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The option was fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.
/s/Robert J Hugin______________________
Robert J Hugin, Attorney-in-Fact
2015-01-06